Bioinformatics-based Screening of Key Genes for Transformation of Tyrosine Kinase Inhibitor-resistant Lung Adenocarcinoma to Small Cell Lung Cancer

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Aug 16

PMID 37583423

Authors

Ying Zhang

Qiang Chen

Ting Huang

Di Zhu

Yuanzhi Lu

Affiliations

Soon will be listed here.

Abstract

Purpose: Lung adenocarcinoma (LUAD) is a common type of lung cancer. Cancer in a small number of patients with EGFR mutations will transform from LUAD to small cell lung cancer (SCLC) during epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapiesr. The purpose of the present study was to identify the core genes related to the transformation of LUAD into SCLC and to explore the associated molecular mechanisms.

Methods: GSE29016, GSE1037, GSE6044 and GSE40275 mRNA microarray datasets from Gene Expression Omnibus (GEO) were analyzed to obtain differentially expressed genes (DEGs) between LUAD and SCLC tissues, and the results were used for network analysis of protein-protein interactions (PPIs). After identifying the hub gene by STRING and Cytoscape platform, we explored the relationship between hub genes and the occurrence and development of SCLC. Finally, the obtained hub genes were validated in treated LUAD cells.

Results: A total of 41 DEGs were obtained, four hub genes (, , and ) were identified, and related prognostic information was obtained. The coexpressed genes of the hub gene set were further screened, and the analysis identified many genes related to the cell cycle. Subsequently, LUAD cell models with TP53 and RB1 inactivation and overexpression of ASCL1 were constructed, and then the expression of hub genes was detected, the results showed that the four hub genes were all elevated in the established cell model.

Conclusion: , , and may affect the transformation of LUAD to SCLC and represent new candidate molecular markers for the occurrence and development of SCLC.

Citing Articles

Specific association of expressions with small cell lung cancer development and chemoradiotherapy outcome.

Hao Y, Lu R, Guo Y, Bao P Saudi Med J. 2024; 45(8):783-790.

PMID: 39074897 PMC: 11288495. DOI: 10.15537/smj.2024.45.8.20230990.

References

Gordon C, Gulzar Z, Brooks J . NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells. Prostate. 2015; 75(5):517-26. DOI: 10.1002/pros.22938. View

Raemaekers T, Ribbeck K, Beaudouin J, Annaert W, Van Camp M, Stockmans I . NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. J Cell Biol. 2003; 162(6):1017-29. PMC: 2172854. DOI: 10.1083/jcb.200302129. View

Kastner S, Voss T, Keuerleber S, Glockel C, Freissmuth M, Sommergruber W . Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression. Mol Cancer Res. 2012; 10(10):1343-58. DOI: 10.1158/1541-7786.MCR-12-0139. View

Wang L, Jin Q, Lee J, Su I, Ge K . Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci U S A. 2010; 107(16):7317-22. PMC: 2867706. DOI: 10.1073/pnas.1000031107. View

Rotow J, Bivona T . Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017; 17(11):637-658. DOI: 10.1038/nrc.2017.84. View

Wu F, Fan J, He Y, Xiong A, Yu J, Li Y . Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021; 12(1):2540. PMC: 8100173. DOI: 10.1038/s41467-021-22801-0. View

Ham J, Kim S, Kim H, Byeon S, Sun J, Lee S . Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. J Thorac Oncol. 2016; 11(1):e1-4. DOI: 10.1016/j.jtho.2015.09.013. View

Quintanal-Villalonga A, Chan J, Yu H, Peer D, Sawyers C, Sen T . Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020; 17(6):360-371. PMC: 7397755. DOI: 10.1038/s41571-020-0340-z. View

Witkiewicz A, Chung S, Brough R, Vail P, Franco J, Lord C . Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Rep. 2018; 22(5):1185-1199. PMC: 5967622. DOI: 10.1016/j.celrep.2018.01.022. View

10.

Rohrbeck A, Neukirchen J, Rosskopf M, Pardillos G, Geddert H, Schwalen A . Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med. 2008; 6:69. PMC: 2613386. DOI: 10.1186/1479-5876-6-69. View

11.

Boyer L, Plath K, Zeitlinger J, Brambrink T, Medeiros L, Lee T . Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006; 441(7091):349-53. DOI: 10.1038/nature04733. View

12.

Hogg D, Guidos C, Bailey D, Amendola A, Groves T, Davidson J . Cell cycle dependent regulation of the protein kinase TTK. Oncogene. 1994; 9(1):89-96. View

13.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

14.

Wood D . National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening. Thorac Surg Clin. 2015; 25(2):185-97. DOI: 10.1016/j.thorsurg.2014.12.003. View

15.

Blomfield I, Rocamonde B, Masdeu M, Mulugeta E, Vaga S, van den Berg D . Id4 promotes the elimination of the pro-activation factor Ascl1 to maintain quiescence of adult hippocampal stem cells. Elife. 2019; 8. PMC: 6805120. DOI: 10.7554/eLife.48561. View

16.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

17.

Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View

18.

Borges M, Linnoila R, van de Velde H, Chen H, Nelkin B, MABRY M . An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997; 386(6627):852-5. DOI: 10.1038/386852a0. View

19.

Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S . ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. Lung Cancer. 2011; 75(1):119-25. DOI: 10.1016/j.lungcan.2011.05.028. View

20.

Winslow M, Dayton T, Verhaak R, Kim-Kiselak C, Snyder E, Feldser D . Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011; 473(7345):101-4. PMC: 3088778. DOI: 10.1038/nature09881. View